Key takeaways:

• Jazz Pharmaceuticals will present a poster on Xywav at the 2026 American Academy of Neurology Annual Meeting in Chicago.
• The research evaluates cognitive complaints, functional impairments, and symptom severity in narcolepsy patients using greater than 9-gram dosages of low-sodium oxybate.
• The presentation is part of a broader showcase of six abstracts highlighting real-world evidence in rare neurological and sleep disorders.

Jazz Pharmaceuticals plc will present clinical data evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago.

The sleep-focused research is part of six abstracts the company is presenting at the meeting. The Xywav poster presentation will highlight data from the DUET study, specifically focusing on patients taking higher dosages of the low-sodium oxybate.

The presentation details are as follows:

• Changes in Self-Reported Cognitive Complaints, Functional Impairments, Work Productivity, and Symptom Severity in Participants With Narcolepsy After Treatment With Greater Than 9 Gram Dosages of Low-Sodium Oxybate in the DUET Study
• P3: Sleep: Pathophysiology (Poster)
• Sunday, April 19, 5-6 pm CT

“Jazz is proud to present research at another AAN Annual Meeting, especially as we continue to sharpen our focus on the significant unmet needs faced by people with rare neurological disorders, including epilepsy and sleep disorders,” says Jessa Alexander, PhD, neuroscience therapeutic area head, global medical and scientific affairs of Jazz Pharmaceuticals, in a release. “Through our ongoing Epidiolex and Xywav research, we are gaining a deeper understanding of these complex conditions, and the real treatment needs patients experience, with data that enriches our view of the patient journey and focuses our R&D efforts on closing persistent gaps in care across rare neurology.”

Xywav is an FDA-approved low-sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy, as well as idiopathic hypersomnia in adults. The therapy contains a unique composition of cations resulting in 92% less sodium than sodium oxybate, reducing the chronic sodium burden for patients.

In addition to the narcolepsy data, Jazz Pharmaceuticals will present five abstracts evaluating Epidiolex (cannabidiol) in patients with severe forms of epilepsy, including Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.